Medtronic Analyst Conference In Brief
This article was originally published in The Gray Sheet
Executive Summary
60 "major" launches planned for 2011: Medtronic plans to launch 60 "major" new products within the next year, including magnetic-resonance-imaging-safe implants, CEO Bill Hawkins told analysts at a June 7 investor and analyst meeting in New York. He noted Medtronic has 25 PMAs under review at FDA, as well as approximately 30 "major" clinical trials. "I have been with the company for nine years, and I cannot remember a time when our pipeline has been as robust and full," Hawkins said. "We are investing roughly 9[%] to 10% of our sales dollars in organic R&D, which translates into about $1.6 billion.
You may also be interested in...
Medtronic Spine Sales Down In Fiscal Q3, But Firm Expects A Rebound In 2011
Medtronic is looking to turn around its flagging spine business by mid-2011, CEO Bill Hawkins said during the firm's Feb. 23 fiscal third quarter earnings call
US FDA Expects Joint AdComm Briefing Document, Oncology Chief Says
The combined format is the new default for briefing advisory committee members, US FDA Oncology Center of Excellence Director Pazdur declared.
Parallel Scientific Advice: Is The EMA User Fee Impacting Interest?
EMA charges participants to receive scientific advice through the fledgling program, unlike the US FDA, which may not fit the budgets of some complex generic sponsors. At the same time, sponsors also may simply not be aware the program exists yet.